
Alaunos Therapeutics Investor Relations Material
Latest events

Q1 2023
Alaunos Therapeutics

Q1 2025
11 Jun, 2025

Q4 2024
30 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alaunos Therapeutics Inc
Access all reports
Alaunos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in T-cell receptor (TCR) therapies, leveraging its proprietary Sleeping Beauty non-viral gene transfer platform to engineer T-cells that target solid tumors with specific genetic mutations. Alaunos’s pipeline targets a range of cancers, including lung, ovarian, and pancreatic cancers. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
TCRT
Country
🇺🇸 United States